Page 2 - Multiple Sleep Latency News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Multiple sleep latency. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Multiple Sleep Latency Today - Breaking & Trending Today

Waterford News and Star — Sleep deprivation of surgeons in Ireland diminishing performance, study says

Waterford News and Star — Sleep deprivation of surgeons in Ireland diminishing performance, study says
waterford-news.ie - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from waterford-news.ie Daily Mail and Mail on Sunday newspapers.

Sarah Mooney , Dale Whelehan , Paul Ridgway , School Of Medicine , Journal Of Surgical Research , Trinity College Dublin , Department Of Surgery , Behaviour Science , Multiple Sleep Latency , Psychomotor Vigilance Task , சாரா மூனி , பால் ரிட்வே , பள்ளி ஆஃப் மருந்து , இதழ் ஆஃப் அறுவை சிகிச்சை ஆராய்ச்சி , திரித்துவம் கல்லூரி டப்ளின் , துறை ஆஃப் அறுவை சிகிச்சை , நடத்தை அறிவியல் , பல தூங்கு தாமதம் ,

Harmony Biosciences Enrolls First Patient In Phase 2 Trial Evaluating Pitolisant For Excessive Daytime Sleepiness In Patients With Prader-Willi Syndrome

Share this article
Share this article
PLYMOUTH MEETING, Pa. and CHICAGO, Dec. 15, 2020 /PRNewswire/ Harmony Biosciences Holdings, Inc. ( Harmony ) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced the first patient has been enrolled in a Phase 2 trial evaluating the safety and efficacy of pitolisant for the treatment of excessive daytime sleepiness (EDS) and other key symptoms in patients with Prader-Willi Syndrome (PWS).
We view pitolisant as a portfolio in a product opportunity and are taking a mechanism-based approach to drug development in managing its life cycle with the goal of expanding its clinical utility, said Harmony s Chief Medical Officer, Jeffrey Dayno, M.D. We believe pitolisant could offer an important therapeutic benefit in people living with PWS based on preclinical models of the disorder, p ....

United States , Baylor College Of Medicine , Jeffrey Dayno , Nancy Leone , Paige Rivard , Lisa Caperelli , John Walter , Foundation For Prader Willi Research , Drug Administration , Prader Willi Syndrome Association United States , Exchange Commission , Harmony Biosciences Holdings Inc , Paragon Biosciences , Harmony Biosciences Holdings , Prader Willi Syndrome , Chief Medical Officer , Prader Willi Research , Chief Executive Officer , Multiple Sleep Latency , Daniel Glaze , Baylor College , Texas Children , Prescribing Information , Plymouth Meeting , Harmony Biosciences , Private Securities Litigation Reform Act ,